Psoriasis news, coffee and melanoma study most read Healio Dermatology articles of week

Recent developments in psoriasis, including FDA approval of Cosentyx for adults with plaque psoriasis, were the most read articles during the past week in Healio Dermatology.

Results of a recently published study showing that at least four cups of caffeinated coffee a day might lead to lower risk of melanoma also was among the top read stories:

Seven recent developments in psoriasis

Recent developments involving psoriasis include the use of tonsillectomy and anti-tumor necrosis factor-alpha agents to help patients with psoriasis, as well as an association between psoriasis and uncontrolled hypertension. Read more

Higher coffee consumption shows ties to decreased melanoma risk

People who consumed at least four cups of caffeinated coffee per day had a lower risk of malignant melanoma, according to recently published study results.

Erikka Loftfield

Erikka Loftfield, MPH, and colleagues conducted a National Institutes for Health- American Association of Retired Persons prospective study by assessing coffee intake in a self-administered, 124-item food frequency questionnaire. Read more

European Commission approves Otezla for psoriasis, psoriatic arthritis

Celgene announced it has received European Commission marketing authorization for Otezla in treating moderate-to-severe chronic plaque psoriasis and psoriatic arthritis in adults.

Otezla (apremilast), an oral selective inhibitor of phosprodiesterase 4, is indicated for treating moderate-to-severe chronic plaque psoriasis in patients who have failed to respond to, have a contraindication to or are intolerant to other systemic therapies including cyclosporine, methotrexate or ultraviolet-A light, according to a press release. Read more

European Commission approves Cosentyx as first-line psoriasis treatment

Novartis announced the European Commission has approved Cosentyx for first-line systemic treatment of moderate-to-severe plaque psoriasis in adults. Read more

FDA approves Cosentyx for adults with plaque psoriasis

The FDA announced it has approved Cosentyx to treat adults with moderate-to-severe plaque psoriasis.

Cosentyx (Novartis) has the active ingredient of secukinumab, an antibody that binds to interleukin-17A (IL-17A), which is involved in inflammation, according to an FDA press release. Through that action, secukinumab prevents IL-17A from binding to its receptor, inhibiting the ability to trigger the inflammatory response in plaque psoriasis. Read more